IKK NBD peptide inhibits LPS induced pulmonary inflammation and alters sphingolipid metabolism in a murine model

Pulmonary Pharmacology and Therapeutics

Volumn 25, Issue 3, 2012, Pages 228-235

  von Bismarck, Philipp ^a   Winoto Morbach, Supandi ^a   Herzberg, Mona ^a   Uhlig, Ulrike ^b   Schütze, Stefan ^a   Lucius, Ralph ^c   Krause, Martin F ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^c UNIVERSITY OF KIEL   (Germany)

Author keywords

Acid sphingomyelinase; Acute lung injury; Ceramide; IKK NBD peptide; Nuclear factor B; Pulmonary inflammation; Sphingosine 1 phosphate

Indexed keywords

CERAMIDE; I KAPPA B KINASE; I KAPPA B KINASE GAMMA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; MONOCYTE CHEMOTACTIC PROTEIN 1; SPHINGOLIPID; SPHINGOMYELIN PHOSPHODIESTERASE; SPHINGOSINE 1 PHOSPHATE; TUMOR NECROSIS FACTOR ALPHA;

ACUTE LUNG INJURY; ANIMAL CELL; ARTICLE; BODY WEIGHT; CELL COUNT; CELL DIFFERENTIATION; ENZYME ACTIVITY; LIPID METABOLISM; LUNG ALVEOLUS EPITHELIUM; LUNG LAVAGE; LUNG PARENCHYMA; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RESPIRATORY TRACT INFLAMMATION;

ACUTE LUNG INJURY; ANIMALS; CELL-PENETRATING PEPTIDES; CERAMIDES; DISEASE MODELS, ANIMAL; FEMALE; I-KAPPA B KINASE; INFLAMMATION; LIPOPOLYSACCHARIDES; LYSOPHOSPHOLIPIDS; MALE; MICE; MICE, INBRED C57BL; NF-KAPPA B; PEPTIDES; PSEUDOMONAS AERUGINOSA; SPHINGOLIPIDS; SPHINGOSINE;

EID: 84860649714     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2012.03.002     Document Type: Article

References (51)

1. Cheng D.S., Han W., Chen S.M., Sherrill T.P., Chont M., Park G.Y., et al. Airway epithelium controls lung inflammation and injury through the NF-kappa B pathway. J Immunol 2007, 178:6504-6513.
2. Skerrett S.J., Liggitt H.D., Hajjar A.M., Ernst R.K., Miller S.I., Wilson C.B. Respiratory epithelial cells regulate lung inflammation in response to inhaled endotoxin. Am J Physiol Lung Cell Mol Physiol 2004, 287:143-152.
3. Ware L.B., Matthay M.A. The acute respiratory distress syndrome. N Engl J Med 2000, 342:1334-1349.
4. May M.J., D'Acquisto F., Madge L.A., Glöckner J., Pober J.S., Ghosh S. Selective inhibition of NF-kappaB activation by a peptide that blocks the interaction of NEMO with the IkappaB kinase complex. Science 2000, 289:1550-1554.
5. Madge L.A., May M.J. Inhibiting proinflammatory NF-kappaB signaling using cell-penetrating NEMO binding domain peptides. Methods Mol Biol 2009, 512:209-232.
6. Strickland I., Ghosh S. Use of cell permeable NBD peptides for suppression of inflammation. Ann Rheum Dis 2006, 65:75-82.
7. von Bismarck P., Klemm K., Wistädt C.F., Winoto-Morbach S., Uhlig U., Schütze S., et al. Surfactant "fortification" by topical inhibition of nuclear factor-kappaB activity in a newborn piglet lavage model. Crit Care Med 2007, 35:2309-2318.
8. Ankermann T., Reisner A., Wiemann T., Krams M., Köhler H., Krause M.F. Topical inhibition of nuclear factor-kappaB enhances reduction in lung edema by surfactant in a piglet model of airway lavage. Crit Care Med 2005, 33:1384-1391.
9. Shibata W., Maeda S., Hikiba Y., Yanai A., Ohmae T., Sakamoto K., et al. Cutting edge: the IkappaB kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks inflammatory injury in murine colitis. J Immunol 2007, 179:2681-2685.
10. Tiruppathi C., Shimizu J., Miyawaki-Shimizu K., Vogel S.M., Bair A.M., Minshall R.D., et al. Role of NF-kappaB-dependent caveolin-1 expression in the mechanism of increased endothelial permeability induced by lipopolysaccharide. J Biol Chem 2008, 283:4210-4218.
11. Uhlig S., Gulbins E. Sphingolipids in the lungs. Am J Respir Crit Care Med 2008, 178:1100-1114.
12. Wadgaonkar R., Patel V., Grinkina N., Romano C., Liu J., Zhao Y., et al. Differential regulation of sphingosine kinases 1 and 2 in lung injury. Am J Physiol Lung Cell Mol Physiol 2009, 296:L603-L613.
13. Takabe K., Paugh S.W., Milstien S., Spiegel S. "Inside-out" signaling of sphingosine-1-phosphate: therapeutic targets. Pharmacol Rev 2008, 60:181-195.
14. MacKichan M.L., DeFranco A.L. Role of ceramide in lipopolysaccharide (LPS)-induced signaling. LPS increases ceramide rather than acting as a structural homolog. J Biol Chem 1999, 274:1767-1775.
15. Cuschieri J., Bulger E., Billgrin J., Garcia I., Maier R.V. Acid sphingomyelinase is required for lipid Raft TLR4 complex formation. Surg Infect 2007, 8:91-106.
16. Carroll J.L., McCoy D.M., McGowan S.E., Salome R.G., Ryan A.J., Mallampalli R.K. Pulmonary-specific expression of tumor necrosis factor-alpha alters surfactant lipid metabolism. Am J Physiol Lung Cell Mol Physiol 2002, 282:L735-L742.
17. Ryan A.J., McCoy D.M., McGowan S.E., Salome R.G., Mallampalli R.K. Alveolar sphingolipids generated in response to TNF-alpha modifies surfactant biophysical activity. J Appl Physiol 2003, 94:253-258.
18. Göggel R., Winoto-Morbach S., Vielhaber G., Imai Y., Lindner K., Brade L., et al. PAF-mediated pulmonary edema: a new role for acid sphingomyelinase and ceramide. Nat Med 2004, 10:155-160.
19. Uhlig S., Göggel R., Engel S. Mechanisms of platelet-activating factor (PAF)-mediated responses in the lung. Pharmacol Rep 2005, 57:206-221.
20. McVerry B.J., Peng X., Hassoun P.M., Sammani S., Simon B.A., Garcia J.G. Sphingosine 1-phosphate reduces vascular leak in murine and canine models of acute lung injury. Am J Respir Crit Care Med 2004, 170:987-993.
21. Peng X., Hassoun P.M., Sammani S., McVerry B.J., Burne M.J., Rabb H., et al. Protective effects of sphingosine 1-phosphate in murine endotoxin-induced inflammatory lung injury. Am J Respir Crit Care Med 2004, 169:1245-1251.
22. Lin W.C., Lin C.F., Chen C.L., Chen C.W., Lin Y.S. Inhibition of neutrophil apoptosis via sphingolipid signaling in acute lung injury. J Pharmacol Exp Ther 2011, 339:45-53.
23. Chang Z.Q., Lee S.Y., Kim H.J., Kim J.R., Kim S.J., Hong I.K., et al. Endotoxin activates de novo sphingolipid biosynthesis via nuclear factor kappa B-mediated upregulation of Sptlc2. Prostaglandins Other Lipid Mediat 2011, 94:44-52.
24. Olert J., Wiedorn K.H., Goldmann T., Kühl H., Mehraein Y., Scherthan H., et al. HOPE fixation: a novel fixing method and paraffin-embedding technique for human soft tissues. Pathol Res Pract 2001, 197:823-826.
25. Wiegmann K., Schütze S., Machleidt T., Witte D., Krönke M. Functional dichotomy of neutral and acidic sphingomyelinases in tumor necrosis factor signaling. Cell 1994, 78:1005-1015.
26. Jensen J.M., Schütze S., Förl M., Krönke M., Proksch E. Roles for tumor necrosis factor receptor p55 and sphingomyelinase in repairing the cutaneous permeability barrier. J Clin Invest 1999, 104:1761-1770.
27. Olivera A., Rosenthal J., Spiegel S. Effect of acidic phospholipids on sphingosine kinase. J Cell Biochem 1996, 60:529-537.
28. Kohama T., Olivera A., Edsall L., Nagiec M.M., Dickson R., Spiegel S. Molecular cloning and functional characterization of murine sphingosine kinase. J Biol Chem 1998, 273:23722-23728.
29. Uhlig U., Fehrenbach H., Lachmann R.A., Goldmann T., Lachmann B., Vollmer E., Uhlig S. Phosphoinositide 3-OH kinase inhibition prevents ventilation-induced lung cell activation. Am J Respir Crit Care Med 2004, 169:201-208.
30. Karin M., Yamamoto Y., Wang Q.M. The IKK NF-kappa B system: a treasure trove for drug development. Nat Rev Drug Discov 2004, 3:17-26.
31. Baima E.T., Guzova J.A., Mathialagan S., Nagiec E.E., Hardy M.M., Song L.R., et al. Novel insights into the cellular mechanisms of the anti-inflammatory effects of NF-kappaB essential modulator binding domain peptides. J Biol Chem 2010, 285:13498-13506.
32. Chen S.M., Cheng D.S., Williams B.J., Sherrill T.P., Han W., Chont M., et al. The nuclear factor kappa-B pathway in airway epithelium regulates neutrophil recruitment and host defence following Pseudomonas aeruginosa infection. Clin Exp Immunol 2008, 153:420-428.
33. Sadikot R.T., Zeng H., Joo M., Everhart M.B., Sherrill T.P., Li B., et al. Targeted immunomodulation of the NF-kappaB pathway in airway epithelium impacts host defense against Pseudomonas aeruginosa. J Immunol 2006, 176:4923-4930.
34. Hashimoto S., Pittet J.F., Hong K., Folkesson H., Bagby G., Kobzik L., et al. Depletion of alveolar macrophages decreases neutrophil chemotaxis to Pseudomonas airspace infections. Am J Physiol 1996, 270:L819-L828.
35. Koay M.A., Gao X., Washington M.K., Parman K.S., Sadikot R.T., Blackwell T.S., et al. Macrophages are necessary for maximal nuclear factor-kappa B activation in response to endotoxin. Am J Respir Cell Mol Biol 2002, 26:572-578.
36. Szarka R.J., Wang N., Gordon L., Nation P.N., Smith R.H. A murine model of pulmonary damage induced by lipopolysaccharide via intranasal instillation. J Immunol Methods 1997, 202:49-57.
37. Haimovitz-Friedman A., Cordon-Cardo C., Bayoumy S., Garzotto M., McLoughlin M., Gallily R., et al. Lipopolysaccharide induces disseminated endothelial apoptosis requiring ceramide generation. J Exp Med 1997, 186:1831-1841.
38. Monick M.M., Mallampalli R.K., Carter A.B., Flaherty D.M., McCoy D., Robeff P.K., et al. Ceramide regulates lipopolysaccharide-induced phosphatidylinositol 3-kinase and Akt activity in human alveolar macrophages. J Immunol 2001, 167:5977-5985.
39. Becker K.A., Gellhaus A., Winterhager E., Gulbins E. Ceramide-enriched membrane domains in infectious biology and development. Subcell Biochem 2008, 49:523-538.
40. Gulbins E., Dreschers S., Wilker B., Grassmé H. Ceramide, membrane rafts and infections. J Mol Med 2004, 82:357-363.
41. Grassmé H., Jendrossek V., Riehle A., von Kürthy G., Berger J., Schwarz H., et al. Host defense against Pseudomonas aeruginosa requires ceramide-rich membrane rafts. Nat Med 2003, 9:322-330.
42. Mathias S., Younes A., Kan C.C., Orlow I., Joseph C., Kolesnick R.N. Activation of the sphingomyelin signaling pathway in intact EL4 cells and in a cell-free system by IL-1 beta. Science 1993, 259:519-522.
43. Cornell T.T., Hinkovska-Galcheva V., Sun L., Cai Q., Hershenson M.B., Vanway S., et al. Ceramide-dependent PP2A regulation of TNFalpha-induced IL-8 production in respiratory epithelial cells. Am J Physiol Lung Cell Mol Physiol 2009, 296:L849-L856.
44. Pavoine C., Pecker F. Sphingomyelinases: their regulation and roles in cardiovascular pathophysiology. Cardiovasc Res 2009, 82:175-183.
45. Medler T.R., Petrusca D.N., Lee P.J., Hubbard W.C., Berdyshev E.V., Skirball J., et al. Apoptotic sphingolipid signaling by ceramides in lung endothelial cells. Am J Respir Cell Mol Biol 2008, 38:639-646.
46. Lindner K., Uhlig U., Uhlig S. Ceramide alters endothelial cell permeability by a nonapoptotic mechanism. Br J Pharmacol 2005, 145:132-140.
47. von Bismarck P., Wistädt C.F., Klemm K., Winoto-Morbach S., Uhlig U., Schütze S., et al. Improved pulmonary function by acid sphingomyelinase inhibition in a newborn piglet lavage model. Am J Respir Crit Care Med 2008, 177:1233-1241.
48. Hallman M., Spragg R., Harrell J.H., Moser K.M., Gluck L. Evidence of lung surfactant abnormality in respiratory failure. study of bronchoalveolar lavage phospholipids, surface activity, phospholipase activity, and plasma myoinositol. J Clin Invest 1982, 70:673-683.
49. Xia P., Wang L., Gamble J.R., Vadas M.A. Activation of sphingosine kinase by tumor necrosis factor-alpha inhibits apoptosis in human endothelial cells. J Biol Chem 1999, 274:34499-34505.
50. Tauseef M., Kini V., Knezevic N., Brannan M., Ramchandaran R., Fyrst H., et al. Activation of sphingosine kinase-1 reverses the increase in lung vascular permeability through sphingosine-1-phosphate receptor signaling in endothelial cells. Circ Res 2008, 103:1164-1172.
51. Majtan J., Majtan V. Dimethyl sulfoxide attenuates TNF-α-induced production of MMP-9 in human keratinocytes. J Toxicol Environ Health A 2011, 74:1319-1322.